This inventor holds 1 USPTO granted patent. Top assignee: Teva Pharmaceutical Industries Limited. Active years: 1991.
Company Filing History:
Years Active: 1991
Title: The Innovations of John A. Kanis
Introduction
John A. Kanis is a notable inventor based in Sheffield, GB. He has made significant contributions to the field of medicine, particularly in the treatment of renal osteodystrophy. His innovative approach has led to the development of a unique patent that addresses critical health issues.
Latest Patents
John A. Kanis holds a patent for a method and composition aimed at improving the treatment of human renal osteodystrophy. This patent, titled "Combination of cholecalciferol derivatives for the treatment of renal," involves the administration of 6-40 mcg/d of 24,25(OH)₂D₃ in combination with 1-alpha(OH)D₃ or 1,25(OH)₂D₃ or DHT₂. The goal is to maintain serum calcium concentrations at 10-11 mg/dl and phosphate concentrations at 5.5-6.0 mg/dl, ensuring that the numerical multiplication product of calcium and phosphate does not exceed 60-65.
Career Highlights
John A. Kanis is associated with Teva Pharmaceutical Industries Limited, where he continues to work on innovative solutions in the pharmaceutical industry. His expertise and dedication have made him a valuable asset to the company and the field of medicine.
Collaborations
Throughout his career, John has collaborated with esteemed colleagues such as Shmuel Edelstein and David Ladkani. These partnerships have fostered an environment of innovation and have contributed to the advancement of medical treatments.
Conclusion
John A. Kanis exemplifies the spirit of innovation in the medical field through his groundbreaking patent and collaborative efforts. His work continues to impact the treatment of renal osteodystrophy, showcasing the importance of research and development in healthcare.